No quarterly revenue total was found in Cellectar Biosciences, Inc.'s SEC filings.
Cellectar Biosciences, Inc. (CLRB) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$6.0 million. As of Jun 30, 2026 it held $34.0 million in cash and investments and $1.5 million in total debt.
Revenue
—
Net income
$-6.93M
-27.2% vs year-ago quarter
Operating cash flow
$-6.01M
-17.5% vs year-ago quarter
Free cash flow
$-6.01M
-23.9% vs prior quarter
EPS
$-0.57
+83.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
9.45M
+196.1% vs year-ago quarter
Net cash
$32.46M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1279704
- Former names
- NOVELOS THERAPEUTICS, INC. (until Feb 11, 2014); COMMON HORIZONS INC (until Jun 2, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$7.2M | -$5.8M | -$5.7M | -$4.9M | -$6.0M |
| Net income | -$6.9M | -$5.7M | -$5.3M | -$4.4M | -$5.4M |
| Diluted EPS | -$0.57 | -$1.33 | -$1.30 | -$1.41 | -$3.39 |
| Operating cash flow | -$6.0M | -$4.8M | -$4.3M | -$4.3M | -$5.1M |
| Free cash flow | -$6.0M | -$4.8M | -$4.4M | — | — |
| Total assets | $36.6M | $11.1M | $15.0M | $14.6M | $13.7M |
| Total liabilities | $6.8M | $6.4M | $5.1M | $5.2M | $6.2M |
| Stockholders' equity | $29.9M | $3.3M | $8.5M | $8.0M | $6.1M |
| Cash and investments | $34.0M | $8.3M | $13.2M | $12.6M | $11.0M |
| Total debt | $1.5M | $1.5M | $410,000 | $433,000 | $454,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jul 10, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Officer or director change
|
May 18, 2026 | May 17, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 1000 Cellectar Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.